Recent advances in the efficient reduction of graphene oxide and its application as energy storage electrode materials

Efficient reduction of graphene oxide (GO) by chemical, thermal, electrochemical, and photo-irradiation techniques has been reviewed. Particular emphasis has been directed towards the proposed reduction mechanisms of GO by different reducing agents and techniques. The advantages of using different kinds of reducing agents on the basis of their availability, cost-effectiveness, toxicity, and easy product isolation processes have also been studied extensively. We provide a detailed description of the improvement in physiochemical properties of reduced GO (RGO) compared to pure GO. For example, the electrical conductivity and electrochemical performance of electrochemically obtained RGO are much better than those of chemically or thermally RGO materials. We provide examples of how RGO has been used as supercapacitor electrode materials. Specific capacitance of GO increases after reduction and the value has been reported to be 100-300 F g(-1). We conclude by proposing new environmentally friendly types of reducing agents that can efficiently remove oxygen functionalities from the surface of GO.

Biocatalytical production of (5S)-hydroxy-2-hexanone

Biocatalytical approaches have been investigated in order to improve accessibility of the bifunctional chiral building block (5S)-hydroxy-2-hexanone ((S)-2). As a result, a new synthetic route starting from 2,5-hexanedione (1) was developed for (S)-2, which is produced with high enantioselectivity (ee >99%). Since (S)-2 can be reduced further to furnish (2S,5S)-hexanediol ((2S,5S)-3), chemoselectivity is a major issue. Among the tested biocatalysts the whole-cell system S. cerevisiae L13 surpasses the bacterial dehydrogenase ADH-T in terms of chemoselectivity. The use of whole-cells of S. cerevisiae L13 affords (S)-2 from prochiral 1 with 85% yield, which is 21% more than the value obtained with ADH-T. This is due to the different reaction rates of monoreduction (1-->2) and consecutive reduction (2-->3) of the respective biocatalysts. In order to optimise the performance of the whole-cell-bioreduction 1 2 with S. cerevisiae, the system was studied in detail, revealing interactions between cell-physiology and xenobiotic substrate and by-products, respectively. This study compares the whole-cell biocatalytic route with the enzymatic route to enantiopure (S)-2 and investigates factors determining performance and outcome of the bioreductions.

Biosimulation of drug metabolism--a yeast based model

Computationally predicting the metabolic fates of drugs is a very complex task which is owed not only to the huge and diverse biochemical network in the living cell, but also to the majority of in vivo transformations that occur through the action of hepatocytes and gastro-intestinal micro-flora. Thus, xenobiotics are metabolised by more than a single cell type. However, the prediction of metabolic fates is definitely a problem worth solving since it would allow facilitate the development of drugs in a way less relying on animal testing. As a first step in this direction, PharmBiosim is being developed, a biosimulation tool which is based on substantial data reduction and on attributing metabolic fates of drug molecules to functional groups and substituents. This approach works with yeast as a model organism and is restricted to drugs that are mainly transformed by enzymes of the central metabolism, especially sugar metabolism. The reason for the latter is that the qualitative functioning of the involved biochemistry is very similar in diverse cell types involved in drug metabolism. Further it allows for using glycolytic oscillations as a tool to quantify interactions of a drug with this metabolic pathway.